Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E35.44 EPS (ttm)1.64 Insider Own0.04% Shs Outstand2.77B Perf Week3.69%
Market Cap160.38B Forward P/E15.42 EPS next Y3.76 Insider Trans-16.57% Shs Float2.77B Perf Month2.80%
Income4.62B PEG10.58 EPS next Q0.91 Inst Own74.80% Short Float1.12% Perf Quarter7.38%
Sales39.39B P/S4.07 EPS this Y-61.60% Inst Trans-0.35% Short Ratio3.48 Perf Half Y11.56%
Book/sh15.79 P/B3.67 EPS next Y1.10% ROA4.60% Target Price61.60 Perf Year3.94%
Cash/sh4.68 P/C12.39 EPS next 5Y3.35% ROE10.20% 52W Range44.16 - 58.06 Perf YTD11.56%
Dividend1.84 P/FCF27.56 EPS past 5Y41.50% ROI6.40% 52W High-0.21% Beta0.67
Dividend %3.18% Quick Ratio1.30 Sales past 5Y-3.00% Gross Margin62.80% 52W Low31.20% ATR0.87
Employees68000 Current Ratio1.60 Sales Q/Q-1.20% Oper. Margin18.20% RSI (14)60.47 Volatility1.30% 1.44%
OptionableYes Debt/Eq0.59 EPS Q/Q20.60% Profit Margin11.70% Rel Volume0.88 Prev Close57.61
ShortableYes LT Debt/Eq0.54 EarningsJul 29 BMO Payout110.40% Avg Volume8.91M Price57.94
Recom2.50 SMA202.55% SMA504.37% SMA20010.57% Volume7,860,517 Change0.57%
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Jul-01-16 03:12PM  Merck (MRK) Stock Climbs After Deal With Brazilian Animal-Health Company
02:39PM  [$$] Merck to Buy Brazilian Animal-Health Company at The Wall Street Journal
12:30PM  Hunting for value
12:05PM  Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A. Business Wire
11:07AM  What Are the Benefits of the Novartis-Xencor Alliance to Xencor?
11:06AM  Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities
10:22AM  Merck CEO Frazier on Immunotherapy, Drug Pricing
08:19AM  Better Buy: GlaxoSmithKline plc vs. Merck at Motley Fool
05:30AM  Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer CNW Group
Jun-30-16 04:06PM  What Are Analysts Thinking about Novo Nordisk?
03:54PM  What Is Xencors XmAb Technology?
03:07PM  What the CHMP Just Recommended for Alkems Riluzole Alkem
10:32AM  Merck And Premier Join Hands To Prevent Fractures For Osteoporosis Patients
08:31AM  Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients Business Wire
Jun-29-16 04:01PM  The 4 Stocks That Boosted the Dow Wednesday at 24/7 Wall St.
03:30PM  $200M deal: Merck & Mass. firm to develop personalized cancer vaccines at
02:52PM  These companies hope to deliver a blockbuster Alzheimers drug
12:12PM  Long-term Brexit Fallout May Take a Toll on These Healthcare Stocks
11:35AM  Dow surges 200 points as market tries to shake off Brexit fear at MarketWatch
09:28AM  Stock Futures Notch Higher; Nike Reverses, Climbs
09:00AM  Research Report Initiated on Select Major Drug Manufacturers Equities
07:00AM  Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer Business Wire
Jun-28-16 06:40PM  The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What? at Motley Fool
04:19PM  FDA approves first pill to treat all forms of hepatitis C
02:28PM  Gilead Sciences: Dominating at
09:14AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : June 28, 2016
Jun-27-16 11:45PM  Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied? at Motley Fool
09:42PM  The Largest Drug Pipelines Will Surprise You
04:02PM  Better Buy: Merck & Co. Inc. vs. AbbVie at Motley Fool
12:23PM  Novo Nordisks Premium Valuation Based on Price-to-Earnings
11:21AM  Why Agenus' Stock Has Stumbled in 2016 at Motley Fool
08:41AM  Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment
08:11AM  Short Sellers Increase Bets Against Major Pharmaceutical Stocks at 24/7 Wall St.
06:00AM  Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Business Wire
Jun-25-16 12:05PM  Can Gilead Sciences Rebound in the Second Half of 2016? at Motley Fool
Jun-24-16 04:39PM  Brexit may make health care stocks a good defensive play at MarketWatch
09:42AM  Why Investors Are Paying a Premium for These 3 Drugmakers at Motley Fool
08:00AM  Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29 Business Wire
03:22AM  German pharma lobby says EU drug regulator must leave London Reuters
Jun-23-16 05:01PM  Sanofi's Likely Sweetener for Medivation Panned
10:59AM  Incyte Reports Epacadostat Combination Study Initiation
Jun-22-16 02:05PM  Whats so groundbreaking about Curis new cancer drug that just began human trials? at
01:50PM  U.S. stocks come under stress as Brexit vote looms at MarketWatch
12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
Jun-20-16 12:30PM  Results of Phase 2 Study of Mercks Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe Business Wire
09:30AM  The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
04:46AM  Calls For Actions Grow Louder
Jun-19-16 03:03PM  Gilead Sciences: Where's the Value? at Motley Fool
07:23AM  3 Top Big Pharma Stocks to Buy Now at Motley Fool
Jun-18-16 11:00AM  Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital
Jun-17-16 04:44PM  U.S. stocks fall as Brexit jitters cast long shadow at MarketWatch
04:16PM  Stocks Fall Ahead Of Brexit Vote; Bad News For Apple
11:06AM  Dow 30 Stock Roundup: Microsoft Acquires LinkedIn, Merck to Buy Afferent Pharmaceuticals
09:45AM  Will Merck Keytruda Surpass Bristol-Myers Opdivo In Immunotherapies Race?
07:35AM  Merck: Keytruda works better than chemotherapy for lung cancer patients at
Jun-16-16 08:33PM  Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil
07:00PM  Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle at Motley Fool
05:12PM  This Key Merck Cancer Drug Just Got a Huge Boost at Fortune
04:52PM  Stocks snap 5-day losing streak; Dow reverses triple-digit loss at MarketWatch
04:46PM  Cavium and Marathon Oil skid, while Kroger and Newmont rise
04:39PM  Mercks Keytruda Extends Lung Cancer Survival As Sole Therapy
04:30PM  U.S. Stocks End Slump As Dow Leads; Merck Gains, But Nike Falls
04:01PM  Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
03:29PM  Stocks Recover To Trade Higher; Acacia Communications Breaks Out
02:58PM  Stocks Cut Losses; Merck Hoists Dow; Hedge Funds Dumping Apple
02:19PM  Now Is the Time to Buy Merck, Cramer Says
11:04AM  Jim Cramer -- Merck Should Be Higher on Positive Treatment News
10:04AM  Nasdaq Undercuts 200-Day; Kroger, Merck Stocks Climb
09:54AM  Cramer's Stop Trading: 'Breakthrough' for Merck
09:36AM  Merck's Keytruda prolongs life in big lung-cancer study
08:15AM  Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer
08:00AM  Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress Business Wire
07:38AM  Merck's stock surges on positive results from cancer-treatment study at MarketWatch
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Business Wire
Jun-15-16 10:23PM  A legendary CEO did something unimaginable by todays standards, and it tells you everything about how America has changed
04:46PM  Relypsa Sales Numbers Surprise to the Upside
03:24PM  This Fund Wants to Make It Easier to Invest in Biotech Stocks at Fortune
08:30AM  Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016 Business Wire
Jun-14-16 06:14PM  Merck's Biosimilar Version of Lantus Tops Phase III Studies
04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
11:08AM  Merck & Co. (MRK) Stock Sliding, Jefferies Lowers Price Target
08:08AM  Should Pfizer Buy This Beaten-Down Immuno-Oncology Company? at Motley Fool
Jun-13-16 05:17PM  This Diabetes Drug Saves Lives. You Can Thank The FDA at Forbes
04:08PM  5 Things Organovo Holdings, Inc. Management Wants You to Know at Motley Fool
01:15PM  Merck receives a big vote of confidence
01:03PM  Tricking the Common Cold Into Destroying Cancer at Motley Fool
12:34PM  Merck Stock Trades Ex-Dividend Monday (MRK) at Investopedia
11:00AM  New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children PR Newswire
10:30AM  Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus® Business Wire
08:50AM  Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
03:57AM  Merck & Co., Inc. :MRK-FR: Earnings Analysis: Q1, 2016 By the Numbers : June 13, 2016
03:16AM  ECB Bond Buying Destabilizes All Financial Markets
Jun-12-16 02:00PM  Put Agenus, Progenics on Your Small-Cap List
Jun-11-16 11:00AM  Merck, Pfizer Double Size of Diabetes Drug Study to Catch Rivals at Bloomberg
11:00AM  Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes Business Wire
Jun-10-16 11:50AM  $1.25B deal: Merck to buy California biopharm firm with potential chronic cough treatment at
11:11AM  Merck Testing 13-Year Resistance (MRK) at Investopedia
10:39AM  Merck acquires Pappas-backed biotech company in deal that could reach $1.25 billion at
10:05AM  Q&A: After scoring 2nd big deal in 5 years, is this CEO the Steph Curry of biotech? at
08:53AM  Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Option Exercise44.9838,6471,738,34255,730May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 20Sale54.8038,6472,117,85617,083May 20 02:34 PM
Golestani ClarkEVP & Chief Info OfficerMay 19Sale54.551,23067,09717,083May 20 02:34 PM
Holston Michael JEVP, General CounselMay 10Option Exercise44.58100,0214,458,989164,301May 12 11:39 AM
Holston Michael JEVP, General CounselMay 10Sale54.50100,0215,451,14564,280May 12 11:39 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 06Option Exercise0.003,335025,928May 09 04:21 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 06Option Exercise0.004,002040,221May 09 04:21 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 06Option Exercise0.002,001015,375May 09 04:21 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLMay 06Option Exercise0.0044,464094,899May 09 04:21 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 06Option Exercise0.004,002033,430May 09 04:20 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise34.445,000172,20016,400Apr 13 03:03 PM
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM